Denali Therapeutics Inc. $DNLI Shares Sold by Segall Bryant & Hamill LLC

Segall Bryant & Hamill LLC reduced its position in Denali Therapeutics Inc. (NASDAQ:DNLI) by 4.9% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 510,543 shares of the company’s stock after selling 26,457 shares during the quarter. Segall Bryant & Hamill LLC’s holdings in Denali Therapeutics were worth $9,802,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Headlands Technologies LLC bought a new position in Denali Therapeutics during the 2nd quarter worth approximately $26,000. Johnson Financial Group Inc. bought a new stake in shares of Denali Therapeutics in the 3rd quarter valued at approximately $29,000. State of Wyoming bought a new stake in shares of Denali Therapeutics in the 2nd quarter valued at approximately $29,000. Fifth Third Bancorp acquired a new stake in shares of Denali Therapeutics during the 1st quarter valued at approximately $55,000. Finally, Aster Capital Management DIFC Ltd acquired a new stake in shares of Denali Therapeutics during the 4th quarter valued at approximately $57,000. Institutional investors and hedge funds own 92.92% of the company’s stock.

Wall Street Analysts Forecast Growth

DNLI has been the subject of a number of research reports. Leerink Partners decreased their price objective on shares of Denali Therapeutics from $40.00 to $35.00 and set an “outperform” rating for the company in a report on Wednesday, April 22nd. UBS Group reissued a “buy” rating on shares of Denali Therapeutics in a report on Tuesday, June 16th. Wedbush restated an “outperform” rating and issued a $26.00 price target on shares of Denali Therapeutics in a research report on Monday, July 13th. Sanford C. Bernstein restated a “hold” rating on shares of Denali Therapeutics in a research report on Monday, June 22nd. Finally, JPMorgan Chase & Co. assumed coverage on shares of Denali Therapeutics in a report on Monday, July 13th. They issued an “overweight” rating and a $29.00 price target for the company. Thirteen research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $35.17.

Denali Therapeutics Stock Performance

Shares of NASDAQ DNLI opened at $23.02 on Monday. The company has a market cap of $3.65 billion, a price-to-earnings ratio of -7.99 and a beta of 1.01. Denali Therapeutics Inc. has a 12-month low of $12.58 and a 12-month high of $27.30. The company has a current ratio of 9.28, a quick ratio of 9.28 and a debt-to-equity ratio of 0.01. The stock’s 50 day simple moving average is $23.12 and its 200 day simple moving average is $21.09.

Denali Therapeutics (NASDAQ:DNLI) last released its quarterly earnings data on Thursday, May 7th. The company reported ($0.69) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.73) by $0.04. During the same period last year, the business posted ($0.78) EPS. Equities research analysts expect that Denali Therapeutics Inc. will post -2.73 EPS for the current year.

Denali Therapeutics Profile

Denali Therapeutics is a clinical‐stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company’s research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali’s approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

Among Denali’s lead programs is an orally delivered leucine‐rich repeat kinase 2 (LRRK2) inhibitor for Parkinson’s disease, and an anti‐TREM2 antibody designed to modulate microglial activity in Alzheimer’s patients.